{
  "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
  "docSlug": "63ec8e773c9b43e7b033b64167026114",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 52,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a side-by-side comparison of two proprietary platforms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/15",
  "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
  "deckJsonHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c.json",
  "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.62,
        "y": 0.62
      },
      "kind": "list",
      "text": "Robust MOAs in Complex Pathologies; Generate Actionable Drug Candidates; Highly Predictive IND-Enabling Activities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "230bca38-3e28-4aab-8ebd-64a04d6b469b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.41,
        "x": 0.04,
        "y": 0.38
      },
      "kind": "list",
      "text": "Purpose-Built Cell Therapy Evidence Capture Engine + Relational Database; Proprietary EXPAND technology; Atomized, Novel Binding Scaffold Generation Engine",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dee54f8a-ec4f-4859-bcd1-18328cae5b51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.62,
        "y": 0.34
      },
      "kind": "list",
      "text": "1. System-Tissue Biology Model Development; 2. Purpose-Built Physical Biochemistry Engine; 3. Predictive Validation Framework",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15721c9c-2f86-4ce8-8d01-6fd205955084",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "808d007e-f01e-465f-ac80-79e264763808",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.525,
        "y": 0.2
      },
      "kind": "title",
      "text": "TME Normalization™ Technology – SMARxT Tissue-Specific Platform Oncology Application",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3eafb702-4a41-4844-8bb5-d1d0df7720c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.33,
        "x": 0.08,
        "y": 0.2
      },
      "kind": "title",
      "text": "N-GENIUS PLATFORM",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86a0bc6c-82a4-47dc-931e-4e05189ee0af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.68,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "N-GENIUS Platform + IMMiXBio™ SMARxT Tissue-Specific™ Platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a79af583-1d52-4a4a-8f64-74787bf1e6e4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 10,
      "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 15,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "ec7f8eed-93e3-495e-a456-08be8d6fdcb8",
      "evidence": "NXC-201 entering large markets at a pivotal moment",
      "position": 1,
      "objective": "Why now for Immix Biopharma's therapies?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}